There is little doubt that Vertex Pharmaceuticals Inc.’s cystic fibrosis transmembrane conductance regulator (CFTR) modulators Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) have changed the face of treatment for cystic fibrosis patients. With the approval of Symdeko (tezacaftor), the base therapy for a triple combination with next-generation CFTR modulators, Vertex’s rule of what is forecast to be an $8.6bn market by 2025 is clear for the foreseeable future.
Vertex’s control of the CF market using its triple combination of CFTR modulators is set to carry on for at least the next 10 years, according to Datamonitor Healthcare
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?